Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hybrid Closed-Loop pump could ease diabetes management

NCT ID NCT05059860

Disease control Sponsor: NHS Lothian Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a hybrid closed-loop insulin delivery system (Control-IQ) in 30 adults with type 1 diabetes. The system combines an insulin pump with a continuous glucose monitor that automatically adjusts background insulin. Participants used the system for 52 weeks, and researchers measured blood sugar control, time in target range, and patient wellbeing. The goal was to see if this technology is effective and acceptable for people in Scotland.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tandem Control-IQ hybrid closed-loop insulin delivery system (insulin pump + continuous glucose monitor)
What this could lead to
If successful, this system could help people with type 1 diabetes spend more time with their blood sugar in a healthy range and reduce dangerous highs and lows.
What could go wrong
This was a small, single-group study with only 30 participants, so results may not apply to everyone. The system still requires manual insulin doses at meals and is not yet routinely available in Scotland.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Jun 2023

Finished

May 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

30 patients with Type 1 diabetes will be recruited in NHS Lothian

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of Type 1 diabetes * Established on the Tandem pump for at least 1 month, using novorapid or humalog insulin * HbA1c 40-90 mmol/mol inclusive within the previous 30 days or taken at screening * Total daily dose of insulin 10-100 units * Willing to attend study visits and complete all study assessments * Able to give informed consent Exclusion Criteria: * Pregnant or planning pregnancy * Any disorder which, in the investigators' opinion might jeopardise the patient's safety or compliance with the protocol * Life expectancy less than one year * Severe renal impairment (eGFR \<30ml/min) * Weight \<25kg * Patients prescribed hydroxycarbamide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes mellitus

Contacts and locations

Locations

  • Professor John McKnight

    Edinburgh, Lothian, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.